RxDoctor Payments Data

Leonido Luznik, MD

Hematology & Oncology · Houston, TXNPI 1518902261

Payments from drug & device makers

$793,725in general payments, 2019–2025

Across 35 payments — averaging $22,678 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$768K
  • F. Hoffmann-la Roche AG$11K
  • Incyte Corporation$7K
  • Gilead$4K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Genentech USA, Inc.$74
  • plus $37 from 1 others

What the payments were for

  • Consulting fees$12,63549%
  • Travel & lodging$12,32947%
  • Food & beverage$1,0694%

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$793,725 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$7,184
Medicare patients
20
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →